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Background: There is biological evidence that the brain opioidergic system plays a critical role in the addictive
properties of nicotine. The purpose of the present study was to examine the associations of single nucleotide
polymorphisms (SNPs) in the genes encoding mu-opioid receptor (MOR) and the MOR-interacting proteins (including
OPRM1, ARRB2, and HINT1) with smoking behaviors in Chinese men.
Methods: A total of 284 subjects (including current and ex-smokers) were recruited. Special questionnaires were used
to assess smoking behaviors including age of smoking initiation, daily cigarette consumption, and Fagerström test for
nicotine dependence (FTND) score. Participant samples were genotyped for six SNPs in the opioid pathway genes:
rs1799971 in OPRM1, rs1045280, rs2036657 and rs3786047 in ARRB2, rs3852209 and rs2278060 in HINT1. Linear and logistic
regression models were used to determine single-locus and haplotype-based association analyses.
Results: There was no significant association between any of SNPs analyzed and smoking behaviors. Logistic regression
analyses under dominant, recessive, and additive models showed no significant associations of the six SNPs with smoking
status (current vs. ex-smokers). After adjustment for age at enrollment and smoking initiation age, HINT1 rs3852209 was
significantly associated with smoking status with an OR of 0.54 (95% CI, 0.31-0.95; P = 0.03) under dominant inheritance
model. No haplotypes in ARRB2 or HINT1 were related to smoking status.
Conclusions: The present study indicates no significant association between common genetic variations in MOR and
MOR-interacting proteins and smoking behaviors in Chinese men, and gives suggestive evidence that HINT1 rs3852209
may be related to smoking status. The findings require confirmation from further studies in additional larger samples.
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Tobacco use remains the leading preventable cause of
death in the world. According to the World Health
Organization (WHO), tobacco use is responsible for the
death of approximately six million people and causes
hundreds of billions of dollars of economic loss world-
wide each year [1]. In 2010, the Global Adult Tobacco
Survey (GATS) China conducted by the Chinese Center
for Disease Control and Prevention reported that 28.1%
of adults in China were current smokers, and the preva-
lence of smoking in men was significantly higher than
that in women (52.9% vs. 2.4%) [1]. There was an* Correspondence: puh3_hb@bjmu.edu.cn
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reproduction in any medium, provided the orestimation of 301 million current smokers in China,
making this country the largest consumer of tobacco in
the world [2]. Cigarette smoking increases the risk of
numerous health problems and causes a variety of
tobacco-related diseases, including primarily cancers,
diabetes, cardiovascular diseases, and chronic lung dis-
eases. Up to half of the world’s 1 billion smokers will
eventually die from a tobacco-related disease [1].
Cessation reverses most adverse effects of smoking.
The majority of smokers are highly motivated to quit,
but confronted with high relapse rate after stopping
smoking [3]. The same issue is confronting the patients
with tobacco-related diseases. Although some smoking
patients quit because of diseases, there is still a consider-
able proportion of them who persist smoking even afterd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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risk factor for their diseases. As several surveys revealed,
the percentage of current smokers accounting for the
patients with tobacco-related diseases was compared to
that of general population [4-6]. Despite great progress in
pharmacological treatment of nicotine dependence, the ef-
ficacy of available treatments is limited, and only 15–30%
of smokers permanently abstain from smoking [3].
Tobacco smoking is believed to be a complex and multi-
factorial behavior with both genetic and environmental
determinants. Recent researches strongly suggested that
smokers varied in their underlying genetic susceptibility
to smoking addiction, and have found significant genetic
influences on several aspects of smoking behaviors, in-
cluding smoking initiation, smoking maintenance and ces-
sation success [7,8]. Variations in several genes have been
suggested to contribute to smoking behaviors, and these
researches have been focused on two broad classes of can-
didate genes: 1) genes that may influence the response to
nicotine (e.g. nicotine metabolism and nicotinic receptors)
and 2) genes that may predispose to addictive behavior
because of their effects on key neurotransmitter pathways
(e.g. dopamine and serotonin) [9,10].
Although multiple neurobiological mechanisms have
been implicated in mediating the reward and reinforcing
effects of drug abuse including nicotine, for the past dec-
ade increasing studies pointed to the endogenous opioid
system, especially the mu-opioid receptor (MOR) [11,12].
Genetic and pharmacological studies indicated that mu-
opioid receptors were mainly involved in nicotine reward
[10,13-16]. These findings have led us to consider the po-
tential role of variations in genes encoding proteins regu-
lating the function of the MOR. Several proteins were
manifested to interact with the MOR in in-vitro models
and had some opioid-related phenotypes demonstrated in
mouse knock-out models [17]. However, it remains uncer-
tain whether and to what extent common genetic variants
in the genes of MOR interacting proteins affect smoking
behaviors on account of limited population data.
Considering higher prevalence of smoking in Chinese
men compared with women, we conducted a cross-
sectional study in Chinese male smokers to explore the
associations between smoking behaviors and genetic
variants in the MOR and MOR-interacting protein
genes, including OPRM1 gene encoding mu-opioid re-
ceptor and two genes encoding mu opioid-receptor-
interacting proteins, namely ARRB2 and HINT1.
Materials and methods
Subjects
Participants were recruited at In-patient Departments of
a general hospital (Peking University Third Hospital) from
February 2011 to February 2012, including Respiratory
Medicine, Cardiology and Endocrinology Departments. Atotal of 284 Chinese males suffering from tobacco-related
diseases were included in this study. All participants
reported themselves as Han nationality and Beijing
local residents. Inclusion criteria were: smokers (con-
tinuous or cumulative smoking six months or more in
lifetime, including current smokers and ex-smokers),
aged 18–80 years old, with one or more of tobacco-related
diseases (including coronary heart disease, atherosclerosis,
cerebrovascular disease, chronic obstructive pulmonary
disease, bronchial asthma, and diabetes mellitus). Exclu-
sion criteria were: patients with drug or alcohol addic-
tion, history of psychiatric illnesses other than nicotine
dependence, or serious clinical conditions and inability
to communicate. In view of remarkable gender differ-
ence in cigarette smoking in China, only male subjects
were involved in the present study to eliminate the pos-
sible gender effect.
In accordance with smoking status at enrollment, partici-
pants were classified into current smokers and ex-smokers,
which were defined as follows: 1) current smokers were
subjects who either were currently smoking at enrollment
or had abstained from smoking for less than one year be-
fore interview; 2) ex-smokers were those who remained
continuously abstinent from cigarettes for at least one year
before the interview. Considering the effect of disease his-
tory on smoking behaviors, the participants were classified
into three groups based on their main tobacco-related dis-
eases diagnosed at admission: cardiovascular and cerebro-
vascular disease, respiratory disease, and diabetes mellitus.
Questionnaire
All individuals provided informed consent for participa-
tion in this study and completed questionnaires asses-
sing demographics and smoking behaviors (including
age of smoking initiation, daily cigarette consumption,
smoking years, and Fagerström test for nicotine depend-
ence (FTND) score at enrollment) [18]. The study proto-
col was approved by the ethics committee of Peking
University Third Hospital.
Genotyping
Peripheral blood was drawn during the enrollment visit,
transported to a central laboratory and stored at -80°C for
further analysis. DNA was extracted from blood leuko-
cytes using a commercial DNA extraction kit (RelaxGene
Blood DNA System, TIANGEN BIOTECH (BEIJING)
CO., LTD.).
Candidate SNPs were selected with regard to minor al-
lele frequency and location in the genes of HINT1 and
ARRB2 from the 5' to 3' regions [19], and practical consid-
erations regarding assay design and resource limitations.
Variants included: rs1799971, an Asn40Asp (A118G) poly-
morphism in exon 1 of the OPRM1 gene located on
chromosome 6; rs1045280, rs2036657 and rs3786047 in
Table 1 Characteristics, smoking behaviors and
distribution of genotypes by smoking status




Age (years)a 56.4 ± 14.8 68.5 ± 8.3 <0.05
Educationb
< 9 years 49 (35.5) 51 (34.9) 0.92




81 (58.7) 91 (62.3) 0.15
Respiratory diseases 38 (27.5) 45 (30.8)
Diabetes mellitus 19 (13.8) 10 (6.8)
Smoking behaviorsa
Age of smoking initiation
(years)
23.6 ± 8.0 28.3 ± 10.8 <0.05
Daily cigarette
consumption (per day)
22.3 ± 11.9 19.9 ± 9.9 0.06
Smoking years (years) 32.9 ± 14.3 31.7 ± 12.3 0.46
Genotypeb
rs1799971d
AA 64 (46.7) 72 (49.3) 0.54
AG 62 (45.3) 58 (39.7)
GG 11 (8.0) 16 (11.0)
rs1045280
CC 2 (1.4) 2 (1.4) 0.99
CT 39 (28.3) 41 (28.1)
TT 97 (70.3) 103 (70.5)
rs2036657
AA 98 (71.0) 103 (70.5) 0.93
AG 38 (27.5) 40 (27.4)
GG 2 (1.4) 3 (2.1)
rs3786047d
AA 1 (0.7) 2 (1.4) 0.87
AG 38 (27.5) 41 (28.1)
GG 98 (71.0) 103 (70.5)
rs3852209
CC 79 (57.2) 99 (67.8) 0.11
CT 53 (38.4) 39 (26.7)
TT 6 (4.3) 8 (5.5)
rs2278060
AA 77 (55.8) 94 (64.4) 0.28
AC 54 (39.1) 44 (30.1)
CC 7 (5.1) 8 (5.5)
aValues are means ± SD.
bValues are n (%). cP value from chi-square and t tests.
dGenetic material for genotyping was available for 283 of the subjects.
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rs3852209 and rs2278060 in HINT1, a 6-kb gene located
on chromosome 5. Using Haploview analysis, high linkage
disequilibriums for SNPs in HINT1 (rs3852209 & rs
2278060: D' = 1.0, r2 = 0.921) and ARRB2 (rs 1045280 & rs
2036657: D' = 0.987, r2 = 0.973; rs 1045280 & rs 3786047:
D' = 1.0, r2 = 0.987; rs 2036557 & rs 3786047: D' = 0.986,
r2 = 0.96) were observed.
Gnotypes were determined by iPLEX/MALDI-TOF
mass spectrometry (Sequenom, Inc.), applying extensive
quality control measures. The capture and extend primers
of SNPs for genotyping were designed with reference to
NCBI genome build 37.1. The genotyping results were
validated by repeating 5% of the total sample; no genotyp-
ing errors were detected. The genotyping call rate for all
subjects was 99.6%-100%.
Statistical analysis
The SPSS 19.0 statistical package was used in the fol-
lowing data analyses. Chi-square tests and t-tests were
used to test differences of baseline variables by smoking
status. The distribution of genotype was compared with
predictable value of the Hardy-Weinberg heredity equi-
librium by the Pearson χ2 test. The associations of SNPs
with smoking status were analyzed by using logistic
regression models adjusted for age at enrollment and
smoking initiation age, which were expressed as odds
ratio (OR) and 95% confidence interval (CI). To determine
the associations between the genotypes and smoking initi-
ation age, daily cigarette consumption and FTND score
respectively, general linear models were used to compare
the differences of continuous variables among different
genotype groups. Age as a covariate was included in linear
models. Linkage disequilibrium was examined by using
Haploview version 4. We constructed haplotypes using
PHASE version 2.0 and examined the associations of hap-
lotypes with smoking status by logistic regression models.
Rare haplotypes (<1%) were omitted from the analyses.
For all analyses, difference with a two-sided P < 0.05 was
considered statistically significant.
Results
Characteristics of the subjects
Of all 284 smokers in the study, 146 (51.4%) were ex-
smokers who successfully quit smoking and remained ab-
stinent for at least one year. The demographic and clinical
characteristics and smoking behaviors were shown by
smoking status in Table 1 (age: 62.6 ± 13.4 years [mean ±
SD], education: education of 64.8% participants were more
than 9 years, smoking status: 138 current smokers and
146 ex-smokers). Compared with ex-smokers, current
smokers were significantly younger (P < 0.05) at enroll-
ment, and smoking initiation age was earlier (P < 0.05)
(Table 1). For ex-smokers, the average age of quitting was
Fang et al. Behavioral and Brain Functions 2014, 10:2 Page 4 of 8
http://www.behavioralandbrainfunctions.com/content/10/1/259.9 years old (SD, 9.8), and the average length of time
since quitting was 8.6 years (SD, 8.4). 115 (83.3%) of
current smokers tried to quit repeatedly and then relapsed
even after a short period of abstinence.
The proportions of cardiovascular & cerebrovascular dis-
eases and respiratory diseases in ex-smokers were higher
than those in current smokers, while the proportions of
diabetes mellitus in ex-smokers and current smokers were
opposite. But the results of Pearson chi-square test indi-
cated that the difference in disease history between current
smokers and ex-smokers did not reach the significant level
(P = 0.15). Multiple comparisons of various disease his-
tories between ex-smokers and current smokers showed
there were no significant differences (cardiovascular &
cerebrovascular disease vs. respiratory disease: P = 0.84;
cardiovascular & cerebrovascular disease vs. diabetes
mellitus: P = 0.07; respiratory disease vs. diabetes melli-
tus: P = 0.07).
Table 2 listed the characteristics of the selected
SNPs. The minor allele frequencies overall were in
concordance with HapMap reference data (Table 2).
The genotype distributions of SNPs in current smokers
and ex-smokers shown in Table 1 fulfilled the expecta-
tions of the Hardy–Weinberg equilibrium.
Polymorphisms and smoking behaviors
General linear models revealed no significant differences
of age of smoking initiation or daily cigarette consumption
in various genotypes of each SNP. The degree of nicotine
dependence of current smokers was ascertained by the
FTND score, and the average FTND score was 3.7 (SD,
2.6). There were no significant associations between SNPs
and FTND scores in current smokers (Table 3).
Polymorphisms and smoking status
To estimate the influence of genetic variation on smok-
ing status, the genotype frequencies of each SNP were
compared by Pearson χ2 test between current smokers
and ex-smokers, and no statistically significant differ-
ences were found (Table 1).
Logistic regression models were performed to calculate
ORs and 95% CIs for SNPs with the probability of beingTable 2 Genotype quality control indicators
Gene Genotype identifier Chromosome position Func
ARRB2 rs3786047 4615098 intron
ARRB2 rs1045280 4622638 synon
ARRB2 rs2036657 4625159 3' nea
HINT1 rs3852209 130496015 intron
HINT1 rs2278060 130500751 intron
OPRM1 rs1799971 154360797 misse
#Calculated by using χ2 test (deviation from Hardy–Weinberg conditions).ex-smokers. For each SNP, we tested for allelic associa-
tions with smoking status under dominant, recessive,
and additive models. All SNPs analyzed had no associa-
tions with smoking status (Table 4). After adjustment for
age at enrollment and age of smoking initiation, logistic
regression models showed that rs3852209 in HINT1
gene was associated with smoking status under the dom-
inant model and the OR was 0.54 (95% CI: 0.31-0.95,
P < 0.05), indicating the individuals with CC genotype
had higher probabilities of smoking cessation compared
with those with T allele (i.e. CT and TT genotypes).
Besides, age was significantly associated with smoking
cessation, the probability of successful quitting increased
with age (OR = 1.09, 95% CI: 1.06-1.11, P < 0.05).
Haplotype analysis
For the ARRB2 SNPs rs 3786047, rs 1045280 and rs
2036657, respectively, the common haplotypes were A-C-
G (15.1%) and G-T-A (84.3%), with the remainder totaling
0.5%. For the HINT1 SNPs rs 3852209 and rs 2278060, re-
spectively, the two common haplotypes were C-A (77.5%)
and T-C (21.1%), and the other C-C was 1.4%. The
frequencies of haplotypes in ARRB2 and HINT1 had no
significant differences between current smokers and ex-
smokers (P > 0.05). No haplotypes showed significant
associations with smoking status. After adjustment for age
at enrollment, smoking initiation age and disease history,
no significant associations were observed between the
haplotypes and smoking status (Table 5).
Discussion
The present study focused on the potential association
of SNPs in genes encoding MOR (OPRM1) and MOR-
interacting proteins (ARRB2 and HINT1) with smoking
behaviors. The results generated from Chinese men with
tobacco-related diseases suggested that HINT1 rs3852209
was significantly associated with smoking status (current
smokers vs. ex-smokers). However, it did not provide
evidence for the effect of variations in OPRM1, ARRB2
and HINT1 genes on smoking behaviors including age
of smoking initiation, daily cigarette consumption, and
FTND score. In addition, the logistic regression analysestion Minor allele frequency (minor allele) p-value#
HapMap-CHB Study population
0.161 (A) 0.153 (A) 0.34
ymous 0.167 (C) 0.155 (C) 0.30
r gene 0.117 (G) 0.155 (G) 0.59
0.225 (T) 0.211 (T) 0.73
0.250 (C) 0.225 (C) 0.94
nse 0.361 (G) 0.307 (G) 1
Table 3 Associations of genotypes with smoking initiation
age (in years), daily cigarette consumption (in cigarettes







AA 25.8 ± 9.3 20.6 ± 10.3 4.1 ± 2.6
AG 25.9 ± 10.1 22.1 ± 12.0 3.5 ± 2.6
GG 27.6 ± 11.0 18.9 ± 8.9 2.7 ± 2.2
β Coefficient (se) 0.05 (1.00) 0.48 (0.84) –0.63 (0.35)
P valueb 0.96 0.56 0.07
rs3786047
AA 26.0 ± 11.8 21.7 ± 17.6 8.0 ± 0.0
AG 24.9 ± 10.2 21.1 ± 9.8 3.9 ± 2.7
GG 26.5 ± 9.7 21.0 ± 11.4 3.6 ± 2.5
β Coefficient (se) 0.05 (1.36) –1.11 (1.13) 0.58 (0.47)
P valueb 0.97 0.33 0.22
rs1045280
CC 23.5 ± 10.8 21.3 ± 14.4 5.0 ± 4.2
CT 24.8 ± 10.2 21.1 ± 9.8 3.9 ± 2.6
TT 26.6 ± 9.7 21.1 ± 11.4 3.6 ± 2.5
β Coefficient (se) –0.14 (1.33) –1.16 (1.11) 0.45 (0.45)
P valueb 0.92 0.29 0.32
rs2036657
AA 26.6 ± 9.6 21.2 ± 11.4 3.7 ± 2.6
AG 24.9 ± 10.2 20.8 ± 9.7 3.8 ± 2.6
GG 21.6 ± 10.3 21.0 ± 12.4 5.0 ± 4.2
β Coefficient (se) –0.39 (1.31) –1.35 (1.09) 0.32 (0.45)
P valueb 0.76 0.22 0.49
rs3852209
CC 26.4 ± 10.5 21.2 ± 11.5 3.5 ± 2.5
CT 25.5 ± 8.7 21.2 ± 10.1 4.2 ± 2.6
TT 24.9 ± 7.9 18.8 ± 9.0 2.5 ± 2.6
β Coefficient (se) –0.60 (1.11) –0.69 (0.93) 0.19 (0.38)
P valueb 0.59 0.46 0.62
rs2278060
AA 26.3 ± 10.6 21.4 ± 11.7 3.5 ± 2.5
AC 25.9 ± 8.6 20.9 ± 9.9 4.2 ± 2.6
CC 23.9 ± 8.4 18.9 ± 8.7 2.4 ± 2.4
β Coefficient (se) –0.86 (1.09) –0.70 (0.92) 0.12 (0.37)
P valueb 0.43 0.44 0.75
aValues are means ± SD.
bLinear regression models were adjusted for age.
cCurrent smokers.
Table 4 Associations of SNPs with smoking status
(ex-smokers vs. current smokers)
Model Crude OR(95% CI)a




Additive 1.00 (0.70–1.43) 0.96 0.99 (0.66–1.48) 0.97
AA vs. AG vs. GG
Dominant 0.90 (0.56–1.43) 0.66 0.87 (0.51–1.48) 0.62
AA vs. AG + GG
Recessive 1.41 (0.63–3.15) 0.40 1.40 (0.57–3.42) 0.46
AA + AG vs. GG
rs3786047
Additive 1.07 (0.66–1.74) 0.77 1.25 (0.71–2.19) 0.42
GG vs. GA vs. AA
Dominant 1.04 (0.62–1.75) 0.85 1.23 (0.68–2.22) 0.47
GG vs. GA + AA
Recessive 1.88 (0.16–21.07) 0.60 2.49 (0.14–43.07) 0.52
GG + GA vs. AA
rs1045280
Additive 0.98 (0.61–1.58) 0.95 1.21 (0.70–2.09) 0.48
TT vs. TC vs. CC
Dominant 0.98 (0.59–1.64) 0.96 1.21 (0.67–2.19) 0.50
TT vs. TC + CC
Recessive 0.94 (0.13–6.79) 0.95 1.48 (0.14–15.76) 0.74
TT + TC vs. CC
rs2036657
Additive 1.04 (0.65–1.66) 0.85 1.26 (0.73–2.16) 0.40
AA vs. AG vs. GG
Dominant 1.02 (0.61-1.70) 0.93 1.25 (0.69-2.26) 0.45
AA vs. AG + GG
Recessive 1.42 (0.23–8.66) 0.70 1.88 (0.21–16.24) 0.56
AA + AG vs. GG
rs3852209
Additive 0.75 (0.50–1.13) 0.17 0.72 (0.45–1.13) 0.15
CC vs. CT vs. TT
Dominant 0.63 (0.39–1.03) 0.06 0.54 (0.31–0.95) 0.03
CC vs. CT + TT
Recessive 1.27 (0.43–3.77) 0.66 1.75 (0.52–5.90) 0.36
CC + CT vs. TT
rs2278060
Additive 0.79 (0.53–1.17) 0.24 0.76 (0.49–1.20) 0.24
AA vs. AC vs. CC
Dominant 0.69 (0.43–1.12) 0.14 0.60 (0.35–1.03) 0.06
AA vs. AC + CC
Recessive 1.08 (0.38–3.07) 0.87 1.56 (0.48–5.03) 0.45
AA + AC vs. CC
aCrude ORs were calculated with 2 × 2 cross-tabulation.
bAdjusted ORs were obtained from binary logistic regression.
OR, odds ratio; CI, confidence interval.
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achieve smoking cessation with age independent of the
other covariates, which was consistent with the results
described in previous trials and survey studies [20,21].
Table 5 Associations between haplotypes and smoking status








C-C 1.31 (0.87–1.97) 0.18 1.35 (0.85–2.15) 0.19
T-C 1.97 (0.45–8.61) 0.36 2.04 (0.40–10.24) 0.38
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siderable percentage of smoking patients with tobacco-
related diseases did not successfully quit smoking, and
were still current smokers. Most of these patients were
willing to quit, especially after having recognized to-
bacco smoking as an independent risk factor for their
diseases. But unfortunately, they were confronted with
as high rate of relapse as general population [22]. From
the above, it can be seen why an ex-smoker is defined as
one who has quit smoking for at least one year. This as-
sertion is supported by the previous evidence that self-
reported cessation for at least one year had the highest
likelihood of continuous abstinence of smoking [23]. In
the present study, 83.3% of current smokers attempted
to quit and used to be abstinent for a short time, but
finally relapsed. Although the average age of current
smokers was lower than that of ex-smokers, both of
current smokers and ex-smokers had the same number
of smoking years at enrollment. Thus, it was indicated
that current smokers initiated smoking earlier than ex-
smokers. Overall, the present study revealed the differ-
ences of smoking behaviors between current smokers
and ex-smokers, and suggested that current smokers
might have more difficulties in quitting.
Although the mesolimbic dopamine hypothesis is the
most influential theory of nicotine reward and rein-
forcement, recent developments in the neurobiology of
nicotine dependence have identified several other neuro-
transmitter systems that may contribute to the addictive
properties of nicotine as well. In this regard, the brain
opioidergic system has been of interest. Nicotine stimu-
lates the release of endogenous peptide β-endorphin
which has the high affinity for the mu-opioid receptor
[24]. The activated mu-opioid receptors suppress the re-
lease of neurotransmitter GABA [25]. Thus, the decrease
of GABA level causes the disinhibition of VTA dopamine
neurons, which leads to the increase of dopamine release
from nucleus accumbens [26]. Presumably, it is the associ-
ation between the opioidergic system and the mesolimbicdopamine system that appeals to explore the role of mu-
opioid receptors in smoking behaviors. The previous stud-
ies using inbred and knockout mice strongly indicated that
the mu-opioid receptor mediated both the positive and
negative reinforcing effects of nicotine. And it was found
that nicotine induced reward effect and dependence was
substantially attenuated in mu-opioid receptor knock-out
mice [10,13]. All these suggest that mu-opioid receptor,
encoded by the gene of OPRM1, is one of the factors
contributing to tobacco addiction, and thus the OPRM1
becomes an attractive candidate gene for smoking behav-
iors in humans. The Asn40Asp (A118G) polymorphism
(rs1799971), located in exon I of OPRM1 gene, induces
functional change of the mu-opioid receptor and becomes
one of the most studied polymorphisms [27]. This mis-
sense SNP rs1799971 causes the substitution of an aspar-
tate (Asp) for an asparagine (Asn) at position 40 in the
amino-acid sequence. The Asp40 (G) variant, related to
the reduced expression of OPRM1, was found to increase
the binding affinity of β-endorphin for the mu-opioid re-
ceptor by three-fold compared with the wild-type Asn40
(A) OPRM1 [13], nevertheless this finding subsequently
failed to be replicated [28,29]. In rodent studies, there was
evidence that OPRM1 G allele might play a role in sus-
ceptibility to nicotine addiction [11]. In the clinical trial,
Lerman and colleagues found that Asn40Asp (A118G)
mis-sense SNP in OPRM1 might predict the treatment
responses to NRT (nicotine replacement therapy). Specif-
ically, the smokers with one or more copies of G allele
(Asp40 variant) were more likely to quit after a course of
NRT than individuals with two copies of A allele [16].
Their results might be explained by the fact that smokers
with G allele could gain more reward from nicotine pro-
vided by NRT and then derived greater benefit from NRT.
However, the present study did not provide strong support
for the role of the OPRM1 polymorphism (rs1799971) in
smoking behaviors. To be specific, there were no statistical
associations identified between the OPRM1 Asn40Asp
(A118G) polymorphism and smoking status as well as
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ation, daily cigarette consumption and nicotine depend-
ence) in Chinese males.
Furthermore, the mu-opioid receptor directly interacts
with multiple proteins called MOR interacting proteins
(MORIPs), and thus MORIPs gene polymorphisms are
considered to influence on the individual susceptibility to
drug dependence. Of the interacting proteins, β-arrestin 2
and mPKCI-1 have demonstrable opioid-related pheno-
types in mouse knock-out model and other in-vitro
models [17]. By binding to phosphorylated MOR, β-
arrestin 2 has been found to be an important regulator of
signal transduction mediated by opioid receptors through
promotion of receptor desensitization and internalization
and plays a role in opioid reward [17,30,31]. ARRB2 is
known as the gene encoding β-arrestin 2. In ARRB2 null
mutant animals, MOR did not undergo desensitization
and then the increased and prolonged antinociceptive
effects were perceived after morphine challenge [32]. In
contrast to β-arrestin 2, mPKCI-1 (known as histidine
triad nucleotide binding protein 1 in humans) encoded by
the gene HINT1 decreases MOR phosphorylation and
desensitization. It has been shown that mPKCI-1 knock-
out mice could develop tolerance to analgesic effect of
morphine much more quickly than wild-type mice [33].
In the present study, the results indicated a significant
association between HINT1 variant rs3852209 and
smoking status. Compared with CC genotype, the sub-
jects with HINT1 rs3852209 T allele were less possible
to achieve smoking cessation. Although it is unknown
how HINT1 rs3852209 T allele affects HINT1 gene
expression, presumably T allele leads to the deficiency
of mPKCI-1 expression, which is incapable to inhibit
MOR desensitization. As a result, the individual with T
allele develops tolerance to nicotine and is susceptible
to nicotine dependence and then less likely to quit
smoking. The haplotype analyses did not provide evi-
dence for the relationship between ARRB2 or HINT1
and smoking status, which is consistent with the results
from the previous clinical NRT trial [19].
After all, this is the primary study exploring the role of
genetic variations of MOR-interacting proteins in smok-
ing behaviors. Several limitations in our study should be
considered. First, one major limitation of this study was
the limited sample size with the power about 20% (OR:
1.2 - 1.3) calculated by Quanto, which was not sufficient
to determine the associations between genetic variations
and smoking behaviors and might lead to false negative
results which meant missed potential positive associa-
tions. Given the minor genetic effects, the results of our
study might be caused by the limited sample size. Fur-
ther studies with sufficient statistical power are required
to verify the present results. Second, the mismatch of
age at enrollment between current smokers and ex-smokers might influence the results to a certain extent,
though the adjustments were adopted. Third, the study
focused on the subjects with tobacco-related diseases
enrolled from a general hospital. Considering the var-
iety of diseases and differences in severity and course of
the diseases, it was difficult to precisely determine the
effect of tobacco-related disease on smoking behavior.
At last, smoking history was accessed by the partici-
pants' self-report without biochemical confirmation for
current smoking status, which might possibly cause
misclassification.
Despite these limitations, the present study preliminarily
investigated the role of genetic variations of the opioid
pathway in smoking behaviors of Chinese men. Our re-
sults revealed no significant association between common
genetic variations in genes encoding MOR and MOR-
interacting proteins and smoking behaviors of Chinese
men, and presented suggestive evidence for the association
between the MOR-interacting protein encoding gene and
smoking status (current smokers vs. ex-smokers). Finally,
further prospective studies need to be replicated in order
to confirm the findings of the present study.
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